Baidu
map

胸心外科

订阅

MedSci主页 / 所有栏目 / 胸心外科

PCI与尿激酶联合应用成功治疗左前降支血栓性病变（图）

2015-12-02 网络 MedSci原创

尿激酶医学图片
关注

PCI与尿激酶联合应用成功治疗左前降支血栓性病变

PCI与尿激酶联合应用成功治疗左前降支血栓性病变

PCI与尿激酶联合应用成功治疗左前降支血栓性病变

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1684163, encodeId=24f016841634d, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Thu Mar 24 21:11:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078158, encodeId=d19f20e815881, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Jan 27 11:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495934, encodeId=f9b9149593427, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614137, encodeId=7287161413e98, content=<a href='/topic/show?id=6c2f4e46739' target=_blank style='color:#2F92EE;'>#尿激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47467, encryptionId=6c2f4e46739, topicName=尿激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dad19501545, createdName=124987c6m42暂无昵称, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=)]
    2016-03-24 s_pl2017

    #联合应用#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1684163, encodeId=24f016841634d, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Thu Mar 24 21:11:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078158, encodeId=d19f20e815881, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Jan 27 11:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495934, encodeId=f9b9149593427, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614137, encodeId=7287161413e98, content=<a href='/topic/show?id=6c2f4e46739' target=_blank style='color:#2F92EE;'>#尿激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47467, encryptionId=6c2f4e46739, topicName=尿激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dad19501545, createdName=124987c6m42暂无昵称, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=)]
    2016-01-27 仁者大医

    #血栓性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1684163, encodeId=24f016841634d, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Thu Mar 24 21:11:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078158, encodeId=d19f20e815881, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Jan 27 11:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495934, encodeId=f9b9149593427, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614137, encodeId=7287161413e98, content=<a href='/topic/show?id=6c2f4e46739' target=_blank style='color:#2F92EE;'>#尿激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47467, encryptionId=6c2f4e46739, topicName=尿激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dad19501545, createdName=124987c6m42暂无昵称, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=)]
    2015-12-04 redcrab

    #激酶#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1684163, encodeId=24f016841634d, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Thu Mar 24 21:11:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078158, encodeId=d19f20e815881, content=<a href='/topic/show?id=53cb89101eb' target=_blank style='color:#2F92EE;'>#血栓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89101, encryptionId=53cb89101eb, topicName=血栓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Jan 27 11:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495934, encodeId=f9b9149593427, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614137, encodeId=7287161413e98, content=<a href='/topic/show?id=6c2f4e46739' target=_blank style='color:#2F92EE;'>#尿激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47467, encryptionId=6c2f4e46739, topicName=尿激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dad19501545, createdName=124987c6m42暂无昵称, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=)]
    2015-12-04 124987c6m42暂无昵称

    #尿激酶#

    0

相关资讯

J Cell Sci：蛋白激酶通过尿激酶促进前列腺癌侵袭转移

蛋白激酶D3（PKD3）虽然已被证明有助于前列腺癌细胞的生长和生存，但其在前列腺癌细胞运动中的作用仍不清楚。 近日，一项刊登在J Cell Sci杂志上的研究表明PKD2和PKD3激活核因子-κB（NF-κB）信号和促进尿激酶型纤溶酶原激活因子（uPA）的表达/激活，而后两者对前列腺癌细胞的侵袭是至关重要的。 沉默内源性PKD2或/和 PKD3的表达能显著降低前列腺癌的细胞迁移和侵袭，同时uP

Baidu
map
Baidu
map
Baidu
map